These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 19778610)

  • 1. Aromatase resistance mechanisms in model systems in vivo.
    Brodie A; Macedo L; Sabnis G
    J Steroid Biochem Mol Biol; 2010 Feb; 118(4-5):283-7. PubMed ID: 19778610
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aromatase and breast cancer.
    Brodie A; Sabnis G; Jelovac D
    J Steroid Biochem Mol Biol; 2006 Dec; 102(1-5):97-102. PubMed ID: 17113978
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trastuzumab reverses letrozole resistance and amplifies the sensitivity of breast cancer cells to estrogen.
    Sabnis G; Schayowitz A; Goloubeva O; Macedo L; Brodie A
    Cancer Res; 2009 Feb; 69(4):1416-28. PubMed ID: 19190349
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aromatase inhibitors and xenograft studies.
    Chumsri S; Sabnis GJ; Howes T; Brodie AM
    Steroids; 2011 Jul; 76(8):730-5. PubMed ID: 21420993
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of second-line antiestrogen therapy on breast tumor growth after first-line treatment with the aromatase inhibitor letrozole: long-term studies using the intratumoral aromatase postmenopausal breast cancer model.
    Long BJ; Jelovac D; Thiantanawat A; Brodie AM
    Clin Cancer Res; 2002 Jul; 8(7):2378-88. PubMed ID: 12114443
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stopping treatment can reverse acquired resistance to letrozole.
    Sabnis GJ; Macedo LF; Goloubeva O; Schayowitz A; Brodie AM
    Cancer Res; 2008 Jun; 68(12):4518-24. PubMed ID: 18559495
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical modeling of endocrine response and resistance: focus on aromatase inhibitors.
    Macedo LF; Sabnis G; Brodie A
    Cancer; 2008 Feb; 112(3 Suppl):679-688. PubMed ID: 18072255
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Model systems: mechanisms involved in the loss of sensitivity to letrozole.
    Brodie A; Jelovac D; Sabnis G; Long B; Macedo L; Goloubeva O
    J Steroid Biochem Mol Biol; 2005 May; 95(1-5):41-8. PubMed ID: 15967659
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Understanding resistance to endocrine agents: molecular mechanisms and potential for intervention.
    Sabnis G; Brodie A
    Clin Breast Cancer; 2010 Feb; 10(1):E6-E15. PubMed ID: 20133251
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Xenograft models for aromatase inhibitor studies.
    Brodie A; Sabnis G; Macedo L
    J Steroid Biochem Mol Biol; 2007; 106(1-5):119-24. PubMed ID: 17611101
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antitumor activity of Z-endoxifen in aromatase inhibitor-sensitive and aromatase inhibitor-resistant estrogen receptor-positive breast cancer.
    Jayaraman S; Hou X; Kuffel MJ; Suman VJ; Hoskin TL; Reinicke KE; Monroe DG; Kalari KR; Tang X; Zeldenrust MA; Cheng J; Bruinsma ES; Buhrow SA; McGovern RM; Safgren SL; Walden CA; Carter JM; Reid JM; Ingle JN; Ames MM; Hawse JR; Goetz MP
    Breast Cancer Res; 2020 May; 22(1):51. PubMed ID: 32430040
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of a novel orally active SERD AZD9496 against hormone dependent post-menopausal breast cancer depends on inhibition of cellular aromatase activity.
    Kazi A; Goloubeva O; Schech A; Yu S; Sabnis GJ
    J Steroid Biochem Mol Biol; 2020 Sep; 202():105697. PubMed ID: 32461092
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aromatase inhibitors and breast cancer.
    Macedo LF; Sabnis G; Brodie A
    Ann N Y Acad Sci; 2009 Feb; 1155():162-73. PubMed ID: 19250202
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activation of mitogen-activated protein kinase in xenografts and cells during prolonged treatment with aromatase inhibitor letrozole.
    Jelovac D; Sabnis G; Long BJ; Macedo L; Goloubeva OG; Brodie AM
    Cancer Res; 2005 Jun; 65(12):5380-9. PubMed ID: 15958587
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of novel retinoic acid metabolism blocking agent (VN/14-1) on letrozole-insensitive breast cancer cells.
    Belosay A; Brodie AM; Njar VC
    Cancer Res; 2006 Dec; 66(23):11485-93. PubMed ID: 17145897
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HDAC inhibitor entinostat restores responsiveness of letrozole-resistant MCF-7Ca xenografts to aromatase inhibitors through modulation of Her-2.
    Sabnis GJ; Goloubeva OG; Kazi AA; Shah P; Brodie AH
    Mol Cancer Ther; 2013 Dec; 12(12):2804-16. PubMed ID: 24092810
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The intratumoral aromatase model: studies with aromatase inhibitors and antiestrogens.
    Brodie AH; Jelovac D; Long B
    J Steroid Biochem Mol Biol; 2003 Sep; 86(3-5):283-8. PubMed ID: 14623522
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New approaches to the understanding of tamoxifen action and resistance.
    Berstein LM; Zheng H; Yue W; Wang JP; Lykkesfeldt AE; Naftolin F; Harada H; Shanabrough M; Santen RJ
    Endocr Relat Cancer; 2003 Jun; 10(2):267-77. PubMed ID: 12790788
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic observations in MCF-7 aromatase xenografts.
    Brodie A; Jelovac D; Macedo L; Sabnis G; Tilghman S; Goloubeva O
    Clin Cancer Res; 2005 Jan; 11(2 Pt 2):884s-8s. PubMed ID: 15701882
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dietary genistein negates the inhibitory effect of letrozole on the growth of aromatase-expressing estrogen-dependent human breast cancer cells (MCF-7Ca) in vivo.
    Ju YH; Doerge DR; Woodling KA; Hartman JA; Kwak J; Helferich WG
    Carcinogenesis; 2008 Nov; 29(11):2162-8. PubMed ID: 18632754
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.